Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by V Diaby
Lifetime Cost-Effectiveness of Adjuvant External Beam Whole Breast Irradiation (EBWBI) in Estrogen Receptor Positive (ER+) Early-Stage Breast Cancer (ESBC) Women: Cardiotoxicity Consideration
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Treatment Constraints for Single Dose External Beam Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer
Clinical and Translational Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines
BMC Health Services Research
Health Policy
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Intraoperative Radiation Therapy Versus Hypofractionated Whole Breast Irradiation in T1N0, ER Positive Patients
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Factors Determining Anthracycline Use in Hormone Receptor Positive, Early Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Medical Oncologists’ Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Accelerated Whole Breast Irradiation in Early Breast Cancer Patients With Adverse Prognostic Features
Oncotarget
Oncology
